NASDAQ / LIVE COMPANY INTELLIGENCE

Acurx Pharmaceuticals, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERACXP
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / ACXP COVERAGE

What’s moving Acurx Pharmaceuticals, Inc. now

Current reporting with the operating signal separated from the noise.

01
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update

Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update

The story matters when it changes Acurx Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

The story matters when it changes Acurx Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2025 Earnings Call Transcript

Acurx Pharmaceuticals, Inc. (ACXP) Q3 2025 Earnings Call Transcript

Investors are testing whether Acurx Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update

Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update

The story matters when it changes Acurx Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Acurx Pharmaceuticals, Inc. (ACXP): Insider Were Buying In Q1 2025

Acurx Pharmaceuticals, Inc. (ACXP): Insider Were Buying In Q1 2025

The story matters when it changes Acurx Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
06
Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering

Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering

The story matters when it changes Acurx Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest ACXP filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-11 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-12 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-12 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-04-16 · Period 2026-04-15SEC ↗8-KMaterial company eventFiled 2026-03-09 · Period 2026-03-09SEC ↗8-KMaterial company eventFiled 2025-09-22 · Period 2025-09-22SEC ↗DEF 14AProxy and shareholder meetingFiled 2025-08-04 · Period 2025-09-16SEC ↗424B3Official SEC filingFiled 2026-05-12SEC ↗
EARNINGS / QUARTERLY TRACKER

Acurx Pharmaceuticals, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.